StockNews.com started coverage on shares of Tenax Therapeutics (NASDAQ:TENX – Get Free Report) in a report issued on Tuesday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.
Tenax Therapeutics Price Performance
TENX opened at $3.36 on Tuesday. The firm has a 50-day simple moving average of $3.35 and a two-hundred day simple moving average of $5.63. Tenax Therapeutics has a 52 week low of $2.77 and a 52 week high of $61.20.
Tenax Therapeutics (NASDAQ:TENX – Get Free Report) last announced its quarterly earnings results on Tuesday, May 14th. The specialty pharmaceutical company reported ($3.12) EPS for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.72). As a group, equities research analysts anticipate that Tenax Therapeutics will post -7.96 EPS for the current fiscal year.
About Tenax Therapeutics
Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
See Also
- Five stocks we like better than Tenax Therapeutics
- Find and Profitably Trade Stocks at 52-Week Lows
- Automaker’s Bold Move to an EV Future: Is It Time to Buy Stock?
- Consumer Discretionary Stocks Explained
- Massive Breakout: This ETF Signals Big Gains for Small-Cap Stocks
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Major Gaming Stock to Watch: Why It’s a Safe Bet Now
Receive News & Ratings for Tenax Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Tenax Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.
